Skip to main content
MedPathMedPath Home
Clinical Trials/2022-502640-12-01
2022-502640-12-01
Not yet recruiting
Phase 1/2

Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients - DART (19-14434)

Oslo University Hospital Hf10 sites in 4 countries130 target enrollmentSeptember 27, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsImfinzi

Overview

Phase
Phase 1/2
Intervention
Not specified
Conditions
Not specified
Sponsor
Oslo University Hospital Hf
Enrollment
130
Locations
10
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
euclinicaltrials.eu
Start Date
September 27, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Oslo University Hospital Hf
Responsible Party
Principal Investigator
Principal Investigator

Åslaug Helland

Scientific

Oslo University Hospital Hf

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Study Sites (10)

Loading locations...

Similar Trials

Active, not recruiting
Phase 1
Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients
EUCTR2019-002537-11-FIOslo University Hospital100
Active, not recruiting
Phase 1
Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patientson-small cell lung cancer (NLCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2019-002537-11-LTOslo University Hospital100
Completed
Not Applicable
Durvalumab after chemoradiotherapy in non-small cell lung cancer harboring driver gene mutation/translocation: a retrospective multicenter study (HOT2101)non-small cell lung cancer
JPRN-UMIN000048100Hokkaido Lung Cancer Clinical Study Group(HOT)88
Completed
Phase 2
Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma. A multicenter, randomized, phase II trial of the German Anal Cancer Study GroupC21Malignant neoplasm of anus and anal canal
DRKS00020739Goethe Universität; Universitätsklinikum Frankfurt Goethe-Universität180
Active, not recruiting
Phase 1
Radiochemotherapy +/- Durvalumab for locally-advanced Anal CarcinomaA multicenter, randomized, phase II trial of the German Anal Cancer Study Groupanal cancer (UICC-Stage IIB-IIIC, incl. T2>4cm Nany )MedDRA version: 21.1Level: PTClassification code 10002136Term: Anal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10002137Term: Anal cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-003005-25-ATniversity Hospital Frankfurt, Goethe University178